SpaceX, Rocket Lab, AST SpaceMobile: Who Actually Gets Paid in the New Space Economy

Everyone wants to own "space." But the most famous space stock is now mostly an AI company, the best-funded challenger is buying a satellite operator to fix its cash flow, and the stock with the most explosive story trades at more than 100 times its sales. Here is what the numbers say after the biggest space earnings week of the year.

The week of November 9, 2026 delivered a rare concentration of space-sector catalysts. Rocket Lab and AST SpaceMobile both reported on November 9, Firefly Aerospace on November 10, and SpaceX is targeting its next Starship test flight for as early as Friday, November 13, pending regulatory approval.

The headlines were loud. Record revenue, record backlogs, new contracts. But headlines are not the same thing as shareholder returns.

What the market is fundamentally mispricing right now is that "space" is no longer one trade. It has split into at least four very different bets: an AI-and-broadband conglomerate priced like a megacap, a well-funded vertically integrated challenger, a pre-revenue network that must still be built, and a set of smaller, cheaper operators the market mostly ignores. They have different economics, different balance sheets, and very different odds.

This note works through each one, with every figure from the companies' own filings unless labelled otherwise, and a valuation snapshot from the November 11, 2026 close.

---

1. The Macro Shift: Space Became an Infrastructure Business

For most of the last decade, investing in space meant betting on a launch vehicle working. That era is ending. The companies now driving the sector's revenue are not selling rides to orbit. They are selling services delivered from orbit: broadband, direct-to-phone connectivity, defense sensing, spacecraft, and, in SpaceX's case, AI computing.

Three things changed in 2026:

1. SpaceX went public. It priced the largest IPO on record at $135 a share in June, raising about $75 billion and valuing the company at roughly $1.77 trillion (CBS News). For the first time, public investors can own the sector's dominant company directly, which changes how every other space stock is valued against it.
2. Backlogs exploded. Rocket Lab ended Q3 with about $3.6 billion of backlog and Firefly with $1.7 billion. Contracted future revenue, not just launch cadence, now anchors these businesses.
3. Consolidation began. Rocket Lab agreed in June to acquire Iridium, the satellite communications operator, for an enterprise value of about $8.0 billion (Rocket Lab).

The real question investors should be asking is no longer "whose rocket works?" It is "who owns the recurring revenue, and who has the balance sheet to keep building until it arrives?"

---

2. Company by Company

SpaceX (SPCX): no longer a space pure play

SpaceX's Q3 2026 results were remarkable, but look at where the money came from (SpaceX Q3 2026 release):

Total revenue rose 161% from $5.6 billion a year earlier, and net income was $4.4 billion against a $1.1 billion loss in Q3 2025.

Here is where things get interesting. The largest segment is now AI, at more than half of revenue. Starlink is the profit engine: $2.37 billion of operating income on $5.25 billion of revenue, a 45% margin by our calculation. And the launch business that made SpaceX famous lost $7 million in the quarter, while launches fell to 35 from 44 a year earlier.

Starlink is still growing fast. Consumer subscribers reached 13.6 million, up from 7.2 million a year earlier, though monthly revenue per consumer fell to $69 from $83 as growth shifted to cheaper plans and markets.

Then there is the spending. Capital expenditures were $19.6 billion in one quarter, and $48.1 billion over nine months against $13.1 billion of operating cash flow. By our calculation that is roughly negative $35 billion of free cash flow year to date. SpaceX can afford it: it held $51.3 billion of cash and $38.6 billion of marketable securities against $38.8 billion of debt and finance leases. But buyers of SpaceX stock are funding one of the largest AI infrastructure build-outs in the world, not just rockets.

My view: SpaceX is an extraordinary business. It is not a cheap one, and it is not a pure space exposure. Anyone buying it "for space" should understand they are mostly buying AI computing and Starlink.

Rocket Lab (RKLB): the best-funded challenger, with a slipped rocket

Rocket Lab's Q3 was strong on almost every operating measure (Rocket Lab Q3 2026 release):

• Revenue: a record $267.8 million, up from $155.1 million, or about 73%.
• Backlog: about $3.6 billion, up 52% from the end of Q2, with nearly $1 billion of new launch contracts and $470 million of Space Systems work signed in the quarter.
• Neutron demand: more than $515 million of Neutron contracts signed in Q3, bringing the pre-flight backlog to 16 missions, with the base price raised to $70 million for several of them.
• Q4 guidance: revenue of $270–290 million and GAAP gross margin of 34–36%.

But two numbers deserve attention. First, Neutron's first launch is now targeted for no earlier than 2027. The medium-lift rocket is central to the long-term thesis, and every month of delay pushes out the revenue in that backlog. Second, Rocket Lab is still unprofitable: a GAAP operating loss of $79.2 million, a net loss of $79.7 million and adjusted EBITDA of negative $18.0 million. It did report positive operating cash flow of $7.2 million for the quarter, though operations used $127.3 million over nine months.

What sets Rocket Lab apart is its balance sheet. It held about $4.7 billion of cash and marketable securities at September 30, and convertible notes have fallen to almost nothing. That cushion is what lets it pursue Iridium.

The Iridium deal changes the company's profile. Iridium shareholders are to receive $27.00 in cash plus Rocket Lab stock, with a notional value of $54 per share. Below a Rocket Lab price of $67.50, the stock portion is fixed at 0.4000 Rocket Lab shares; above $112.50 it is fixed at 0.2400 shares; in between, it is worth exactly $27.00 (Rocket Lab S-4). Closing is expected in mid-2027, and Rocket Lab says the cash portion is fully funded. Iridium brings what Rocket Lab lacks: a profitable, cash-generating satellite network, with about $278 million of trailing free cash flow according to Stock Analysis.

My view: Rocket Lab has the strongest balance sheet among the public challengers, and Iridium would add real cash flow. But at about 42 times trailing sales, the market is already paying for Neutron to succeed.

AST SpaceMobile (ASTS): the biggest story, the biggest gap to close

AST is building a space-based cellular broadband network that connects directly to ordinary phones. Its Q3 2026 update showed progress, but also how far it still has to go (AST SpaceMobile Q3 2026 presentation; Q3 call):

• Revenue: $42.3 million in Q3, with full-year 2026 guidance of $150–200 million reaffirmed.
• Network: 12 BlueBird satellites unfolded and operating, with BlueBird 7 written off. The company targets about 45 in orbit by mid-2027 and more than 100 deployed under its launch agreements across 2027 and 2028.
• Service: "initially intermittent nationwide coverage in key markets by year-end 2026," with beta trials in early 2027.
• Spending: Q4 adjusted operating expenses guided to $130–140 million and Q4 capital expenditures to $400–500 million.
• Funding: over $3.2 billion of cash, cash equivalents and restricted cash, including $434.6 million restricted, after issuing $1.15 billion of 1.625% convertible notes due 2034.
• Government: an approximately $100 million US Space Force contract, and 16 US government awards to date.

This is where the investment thesis either works or falls apart. AST's value depends on deploying roughly 100 satellites on schedule, turning intermittent coverage into continuous service, and converting carrier partnerships into paying revenue. None of that has happened yet at scale. Meanwhile, the share count rose about 25% over the past year according to Stock Analysis, and the company carries more debt than cash on that site's measure.

My view: AST has the most explosive potential outcome in the group and the widest range of outcomes. It is an execution bet, not a valuation bet.

Firefly Aerospace (FLY): the quiet grower

Firefly gets a fraction of the attention, but its Q3 was notable (Firefly Q3 2026 release):

• Revenue: $110.7 million, up 259% year over year, driven mainly by spacecraft work.
• Backlog: a record $1.7 billion, up from $1.5 billion a quarter earlier.
• Guidance: 2026 revenue raised to $440–450 million.
• Balance sheet: $409.3 million of cash plus $125.4 million of short-term investments, against roughly $25 million of notes payable after repaying a $260 million revolving facility this year.
• Still losing money: a Q3 net loss of $94.2 million.

Firefly's Alpha rocket is transitioning to a new Block II configuration, its Eclipse rocket is in engine qualification, and its Blue Ghost lunar lander program continues. Launch is still a small share of revenue. For now, Firefly is mostly a spacecraft and defense business.

---

3. The Financial Reality

Revenue growth is everywhere in this sector. Cash generation is not.

Quarterly revenue from company releases. TTM free cash flow, cash and debt from Stock Analysis as of the November 11, 2026 close; definitions differ from company-reported figures (for example, AST reports $3.2 billion including restricted cash). Dashes mean we did not pull a comparable figure.

If you look closely at the balance sheets, only one company in this group generates free cash flow today: Iridium. Every other name is spending more than it brings in. That is normal for companies building infrastructure, but it means their equity value depends on continued access to capital, and on the build-out eventually paying off.

Dilution is the hidden cost. AST's share count rose about 25% in a year. Rocket Lab used an at-the-market equity offering to fund the Iridium cash. SpaceX raised about $75 billion in its IPO. When companies fund growth by selling shares, existing owners pay part of the bill.

---

4. The Contrarian Opportunity

Insight 1: The cheapest way to own a space build-out may be the boring company being acquired

Iridium closed at $47.29 on November 11. Under the deal terms, each share would receive $27.00 of cash plus 0.4000 Rocket Lab shares while Rocket Lab trades below $67.50. At Rocket Lab's $66.15 close, that package was worth about $53.46, roughly 13% above Iridium's price, by our calculation.

That gap is not free money. It reflects the time to a mid-2027 close, regulatory approval risk, and the fact that the stock portion falls with Rocket Lab's share price below the collar. But it is a very different kind of space exposure, anchored by a cash-generating network rather than a rocket that has not flown.

Insight 2: Firefly is the only high-growth name trading at a "normal" growth multiple

On enterprise value to trailing sales, Firefly trades at about 11 times, against roughly 42 times for Rocket Lab, 58 times for SpaceX and 109 times for AST, according to Stock Analysis. Firefly's growth is real (revenue up 259% in Q3), and its backlog is now more than four times its trailing revenue. The market may be discounting it for its launch history and smaller scale, but the gap in multiples is large.

Insight 3: SpaceX's success is not automatically good for the others

Starlink's direct-to-phone service competes with AST's core proposition, and it is backed by a company with far more capital. SpaceX's launch prices set the ceiling Rocket Lab and Firefly can charge. A dominant SpaceX is a competitor first and a customer second.

Where expectations may be too high

AST's valuation implies the network works, on schedule, at scale, and that carriers pay meaningfully for it. Rocket Lab's implies Neutron flies and fills its manifest. SpaceX's implies AI computing and Starlink keep compounding at extraordinary rates. All three can be true. The prices leave little room if one is not.

---

5. Valuation: What Has to Go Right?

The question of which of these could "multiply" comes down to how far each company has to grow just to justify today's price. The table below is purely illustrative arithmetic, not a forecast: it asks how much revenue each company would need for its current enterprise value to equal a given multiple of sales.

Enterprise values and trailing revenue from Stock Analysis at the November 11, 2026 close. The target multiples are hypothetical choices for comparison; they are not price targets.

The market is pricing in years of hypergrowth everywhere, but the underlying economics suggest the hurdle is very different by company. Firefly needs to roughly double revenue to reach a modest multiple. AST needs to grow almost ninefold from this year's guidance just to reach 10 times sales. That is why "the stock that could multiply" and "the cheapest stock" are rarely the same company.

---

6. The Five-Year Outlook

Bull case

Starship becomes routinely reusable, Neutron flies in 2027 and ramps, AST's constellation reaches commercial scale with carriers paying, and defense spending on space keeps rising. In this world the growth names grow into their valuations, and AST, with the widest gap to close, has the most to gain. Rocket Lab with Iridium becomes a true end-to-end space company with recurring revenue.

Base case

The sector keeps growing quickly, but slower than current prices imply. Neutron flies later than hoped; AST's deployment slips by quarters rather than years; SpaceX keeps compounding but its AI spending weighs on free cash flow. Returns diverge sharply by balance sheet: companies with cash and backlog keep executing, and those needing frequent capital raises dilute holders along the way.

Bear case

A failed Starship campaign, a Neutron failure, or an AST deployment setback coincides with tighter capital markets. Unprofitable names with heavy capex face expensive financing or deep dilution. High multiples compress quickly, regardless of how strong the long-term story is.

We are deliberately not assigning price targets to these scenarios.

---

7. Positioning: How I Would Think About It

This is a framework for thinking about the sector, not a recommendation for anyone's situation and not a set of position sizes.

For a sector this volatile, building any exposure gradually, and around known catalysts rather than ahead of them, is a common way to manage the risk of buying at a peak in enthusiasm. Revisit after each earnings cycle and each major launch.

---

8. What Could Prove This Thesis Wrong?

1. Starship works sooner and better than expected. Dramatically cheaper heavy launch could compress competitors' pricing and accelerate Starlink, widening SpaceX's lead over everyone.
2. AST executes on schedule. If 45 satellites are in orbit by mid-2027 and carriers pay at scale, today's valuation could look conservative.
3. Neutron flies early and reliably. That would validate Rocket Lab's premium and its pricing power.
4. Capital markets stay wide open. Cheap equity and debt would let unprofitable builders keep spending without painful dilution.
5. Government spending shifts. Defense and space budgets drive a large share of these companies' revenue and can change with policy.

The catalysts to monitor

1. Starship Flight 15, targeted for as early as November 13 pending approval, with a first attempt to catch the upper stage at the tower.
2. AST's next launches: BlueBirds 14–16 are at Cape Canaveral awaiting a SpaceX launch date; 17–19 are due on Blue Origin in early Q1 2027.
3. Rocket Lab's Q4 results against its $270–290 million guidance, and any update to Neutron's 2027 debut.
4. Iridium deal milestones: regulatory approvals and the mid-2027 close.
5. Firefly's Alpha Block II return to flight and Eclipse's engine qualification.
6. SpaceX's free cash flow as AI capital spending continues.

---

The Investment Verdict

The space sector has never had more real revenue, more contracted backlog, or more ways to invest in it. But the most important insight from this earnings week is that the sector's economics have split.

My highest conviction is that balance sheets will decide the winners in the next five years more than rocket specifications. Rocket Lab has the strongest one among the challengers, and Iridium would add the cash flow it lacks. The asymmetric opportunity, with real risk attached, is in the names the market prices like ordinary companies rather than like the future: Firefly on growth, and Iridium on the deal. I would approach AST cautiously, not because the idea is bad, but because the price already assumes it works. And I would remember that SpaceX, for all its brilliance, is now as much an AI bet as a space bet.

In space, the rocket gets the headlines, but the recurring revenue gets the returns.

Data: company earnings releases, SEC filings and earnings calls as linked; IPO details from CBS News; valuation snapshot from Stock Analysis at the November 11, 2026 close. Derived figures are our calculations and are labeled as such.